Zelira Therapeutics Ltd., a global leader in the research and development of clinically validated cannabinoid medicines, has launched the Zelira Dermatology Business’ first product line, Raf Five, through its subsidiary, Zelira Dermatology.
The five-product Raf Five line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads.
The products include known skin-boosting ingredients hyaluronic acid, niacinamide, glycerin, thiotaine (derived from mushrooms), and peptides. The Raf Five line is Zelira’s first step into the acne medication market valued at more than $11 billion worldwide.
Available now in the United States at www.raffive.com, Raf Five bills itself as the only skin care line in the world to feature Zylorma, a patent-pending acne fighting complex developed by Zelira and U.S. board-certified cosmetic dermatologist Dr. Karyn Grossman.
“I am thrilled to be a part of the new Zelira Dermatology and to have teamed up with Zelira to create Zylorma and the Raf Five skin care line,” said Grossman. “Zelira is already known as a leader in cannabinoid research and development for the medical cannabis market, so when they offered me the opportunity to use my medical expertise alongside their ground-breaking scientific formulations to create a truly new and unique solution for acne, I couldn’t pass it up.”
Zylorma uses a proprietary formulation with CBD, salicylic acid and additional botanical compounds to fight bacteria and clogged pores associated with acne, and balance sebum production to help eliminate and prevent acne breakouts. Raf Five uses pharmaceutical-grade CBD isolate derived from hemp and is THC-free.
Grossman explained that in her medical practice she has spent many years treating patients suffering from acne and has seen firsthand their struggle to find effective treatments. She’s excited to see the results from ongoing patient study and the marked improvement after using the Raf Five products.
“I believe that science has just started to skim the surface of the skin-healing properties of cannabinoids,” she said. “Raf Five is only the beginning.”
Zelira also conducted a rigorous industry standard consumer use study for the Raf Five franchise that showed improvement in all of the participants during the 28 day study. Results showed significant improvement as early as seven days for some of the participants.
Zelira’s Dermatology subsidiary is currently developing several other topical products, anticipated to be launched in 2022, including anti-aging, sexual health/intimacy, and specific skin conditions such as psoriasis.
Zelira Therapeutics is a leading global biopharmaceutical company manufacturing and marketing cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world’s largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.